NCT07158918
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07158918
Title ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors ABL Bio, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS

Facility Status City State Zip Country Details
UH Cleveland Medical Center NOT_YET_RECRUITING Cleveland Ohio 44106 United States Details
PASO Medical NOT_YET_RECRUITING Frankston Victoria 3199 Australia Details
Seoul National University Bundang Hospital RECRUITING Seongnam 13620 South Korea Details
Seoul National University Hospital RECRUITING Seoul 03080 South Korea Details
Asan Medical Center NOT_YET_RECRUITING Seoul 05505 South Korea Details
Samsung Medical Center NOT_YET_RECRUITING Seoul 06351 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field